B-cell Lymphoma (BCL)
B-cell lymphoma (BCL) is a type of cancer that originates from B cells, a type of white blood cell responsible for producing antibodies. Our company is at the forefront of B-cell lymphoma drug and therapy development. We employ a multidisciplinary approach, combining expertise in molecular biology, pharmacology, and preclinical research to identify and develop novel targeted therapies for B-cell lymphoma.
Overview of B-cell Lymphoma (BCL)
B-cell lymphoma (BCL) is a group of malignancies that arise from abnormal B cells. These cancerous cells can accumulate and form tumors in various parts of the body, such as lymph nodes, bone marrow, and other lymphoid tissues. Various genetic mutations, translocations, and chromosomal rearrangements have been identified in B-cell lymphomas. For example, the translocation t (14;18) involving the BCL2 gene is frequently observed in follicular lymphoma and leads to overexpression of the anti-apoptotic protein BCL-2.
Furthermore, dysregulation of signaling pathways, such as the B-cell receptor (BCR) pathway and the nuclear factor-kappa B (NF-κB) pathway, plays a critical role in B-cell lymphomagenesis. These pathways contribute to the survival and proliferation of malignant B cells, allowing them to evade apoptosis and promote tumor growth.
Fig.1 Targeting anti-apoptotic BCL-2 family members for therapy. (Adams C. M., et al., 2019)Targeted Therapies of B-cell Lymphoma (BCL)
- BCL-2 Targeted Therapy
The anti-apoptotic protein BCL-2 has gained significant attention. Overexpression of BCL-2 in B-cell lymphomas confers a survival advantage to cancer cells, contributing to therapy resistance. Inhibiting BCL-2 using BH-3 mimetics, such as venetoclax, has shown promising results in clinical trials.
- BCR Targeted Therapy
Molecules involved in the B-cell receptor (BCR) pathway can be used as potential targets, such as Bruton's tyrosine kinase (BTK) and phosphoinositide 3-kinase (PI3K). Inhibitors targeting these molecules have demonstrated efficacy in certain subtypes of B-cell lymphoma, providing new options for drug and therapy development for pharmaceutical companies.
Our Services
With a deep understanding of the pathogenesis and molecular targets involved in B-cell lymphoma, we specialize in the development of diagnostics and targeted therapies. Our team of experts specializes in identifying and optimizing drug candidates and therapies that target the underlying mechanisms of B-cell lymphoma, thereby providing global pharmaceutical companies with more effective and tailored solutions.
Types of BCL Study
Our BCL therapy development platforms
At our company, we have cutting-edge facilities, state-of-the-art equipment, and animal models, all of which are available for comprehensive research on B-cell lymphoma. These animal models are carefully selected and tailored to simulate the complexity of the disease. Our availability of diverse animal species provides an invaluable platform for not only evaluating the safety of potential therapeutics but also delving into the complex realm of pharmacokinetics.
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Adams C. M., et al. "Targeting the Bcl-2 family in B cell lymphoma." Frontiers in oncology 8 (2019): 636.
- Davids, Matthew S. "Targeting BCL-2 in B-cell lymphomas." Blood, The Journal of the American Society of Hematology 130.9 (2017): 1081-1088.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.